Alterations in D1/D2 synergism may account for enhanced stereotypy and reduced climbing in mice lacking dopamine D2L receptor

Brain Research

Volumn 967, Issue 1-2, 2003, Pages 191-200

  Fetsko, Leah A ^a   Xu, Rong ^a   Wang, Yanyan ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Amphetamine; Apomorphine; D1 D2 interaction; D2L knockout mouse; Quinpirole

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; AMPHETAMINE; APOMORPHINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; QUINPIROLE; SKF 8129;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; BITE; CLIMBING; CONTROLLED STUDY; HEAD MOVEMENT; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; STEREOTYPY; WILD TYPE;

EID: 0037470850     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)04277-4     Document Type: Article

References (34)

1. Angrist B., Gershon S. Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects. Adv. Biochem. Psychopharmacol. 16:1977;677-680.
2. Arnt J., Hyttel J., Perregaard J. Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Eur. J. Pharmacol. 133:1987;137-145.
3. Asher I.M., Aghajanian G.K. 6-Hydroxydopmaine lesions of olfactory tubercles and caudate nuclei: effect on amphetamine-induced stereotyped behavior. Brain Res. 82:1974;1-12.
4. 2 dopamine agonists in intact rats. Brain Res. 504:1989;276-283.
5. Bradbury A.J., Cannon J.G., Costall B., Naylor R.J. A comparison of dopamine agonist action to inhibit locomotor activity and to induce stereotyped behaviour in the mouse. Eur. J. Pharmacol. 105:1984;33-47.
6. Braun A.R., Laruelle M., Mouradian M.M. Interactions between D1 and D2 dopamine receptor family agonists and antagonists: the effects of chronic exposure on behavior and receptor binding in rats and their clinical implications. J. Neural. Transm. 104:1997;341-362.
7. Castellanos F.X. Toward a pathophysiology of attention-deficit/hyperactivity disorder. Clin. Pediatrics. 36:1997;381-393.
8. 2 receptor antagonist, (-) eticlopride. Pharmacol. Res. 31:1995;261-267.
9. Jackson D.M., Jenkins O.F., Ross S.B. The motor effects of bromocriptine - a review. Pychopharmacology. 95:1988;433-446.
10. Kelly M.A., Rubinstein M., Asa S.L., Zhang G., Saez C., Bunzow J.R., Allen R.G., Hnasko R., Ben-Jonathan N., Grandy D.K., Low M.J. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice. Neuron. 19:1997;103-113.
11. Kelly M.A., Rubinstein M., Phillips T.J., Lessov C.N., Burkhart-Kasch S., Zhang G., Bunzow J.R., Fang Y., Gerhardt G.A., Grandy D.K., Low M.J. Locomotor activity in D2 dopamine receptor deficient mice is determined by gene dosage, genetic background, and developmental adaptations. J. Neurosci. 18:1998;3470-3479.
12. Kuczenski R., Segal D.S. Sensitization of amphetamine-induced stereotyped behaviors during the acute response: role of D1 and D2 dopamine receptors. Brain Res. 822:1999;164-174.
13. Kurlan R., O'Brien C. Spontaneous movement disorders in psychiatric patients. Long A.E., Weiner W.J. Drug-induced Movement Disorders. 1992;257-280 Futura Publishing Company, New York.
14. Langtry H.D., Clissold S.P. Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease. Drugs. 39:1990;491-506.
15. Langston J.W., Irwin I., Ricaurte G.A. Neurotoxins, Parkinsonism, and Parkinson's disease. Pharm. Ther. 32:1987;19-49.
16. Marshall J.F., Ruskin D.N., LaHoste G.J. D1/D2 dopamine receptor interactions in basal ganglia functions. Neve K.A., Neve R.L. The Dopamine Receptors. 1997;193-219 Humana Press, NJ.
17. Mashurano M., Waddington J.L. Stereotyped behavior in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK&F 38393. Neuropharmacology. 25:1986;947-949.
18. Meltzer H.Y., Park S., Kessler R. Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc. Natl. Acad. Sci. USA. 96:1999;13591-13593.
19. Moore N.A., Axton M.S. Production of climbing behaviour in mice requires both D1 and D2 receptor activation. Psychopharmacology. 94:1988;263-266.
20. Neve K.A., Neve R.L., Fidel S., Janowsky A., Higgins G.A. Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation. Proc. Natl. Acad. Sci. USA. 88:1991;2802-2806.
21. 2 receptor binding in the basal ganglia. Psychol. Med. 24:1994;423-429.
22. Protais P., Costentin J., Schwartz J.C. Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology. 50:1976;1-6.
23. Ralph R.J., Varty G.B., Kely M.A., Wang Y.M., Caron M.G., Rubinstein M., Grandy D.K., Low M.J., Geyer M.A. The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. J. Neurosci. 19:1999;4627-4633.
24. Schmitz Y., Lee C.J., Schmauss C., Gonon F., Sulzer D. Amphetamine distorts stimulation- dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J. Neurosci. 21:2001;5916-5924.
25. Smith J.W., Fetsko L.A., Xu R., Wang Y. Dopamine D2L receptor knockout mice display deficits in positive and negative reinforcing properties of morphine and in avoidance learning. Neuroscience. 10:2002;755-765.
26. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J. Neurosci. 15:1995;4102-4108.
27. Vasse M., Chagraoui A., Protais P. Climbing and stereotyped behaviours in mice require the stimulation of D-1 dopamine receptors. Eur. J. Pharmacol. 148:1988;221-229.
28. Vukhac K.-L., Sankoorikal E.-B., Wang Y. Dopamine D2L receptor- and age-related reduction in offensive aggression. NeuroReport. 12:2001;1035-1038.
29. Wang Y., Xu R., Toshikuni S., Tonegawa S., Kung M.-P., Sankoorikal E.-B. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J. Neurosci. 20:2000;8305-8314.
30. Wang Y., Xu R., Sasaoka T., Sankoorikal E.-B. Dopamine D2L receptor knockout mouse provides a unique model system for studying the functions of D2L and D2S. Nagatsu T., Nabeshima T., McCarty R., Goldstein D.S. Catecholamine Research: From Molecular Insights to Clinical Medicine: Advances in Behavioral Biology. Vol. 53:2002;175-178 Kluwer Academic/Plenum Publishers, New York.
31. Xu R., Hranilovic D., Fetsko L.A., Bucan M., Wang Y. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice. Mol. Psychiatry. 7:2002;1075-1082.
32. Xu M., Moratalla R., Gold L.H., Hiroi N., Koob G.F., Graybiel A.M., Tonegawa S. Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell. 79:1994;729-742.
33. Xu R., Parlow A.F., Wang Y. The effects of dopamine and D2 receptor antagonists on pituitary hormone secretion are intact in mice lacking dopamine D2L receptor. Brain Res. 939:2002;95-99.
34. Zhou L.W., Qin Z.-H., Weiss B. Downregulation of stereotyped behavior and production of latent locomotor behaviors in mice treated continuously with quinpirole. Neuropsychopharmacology. 4:1991;47-55.